Sorry, your browser is out of date. To view this page correctly, please install a modern browser (Microsoft Edge, Firefox or Google Chrome).
SAI - Detailed view
Please log in as a company employee using your SIMIS-Login. For further information please see the FAQ.
DARZALEX SC Inj Lös 1800 mg/15ml Durchstf 15 ml
Drug
DARZALEX SC, Injektionslösung
Multiples Myelom, Leichtketten-Amyloidose
07.16.1. – cytostatics
HAM – Human medicine
LSINJ – Solution for injection
BT – biological medicines
A – Dispensed once only on prescription by a physician or veterinarian (A)
Z – approved
8/13/2020
12/31/9999
Dosage strength
DARZALEX SC 1800 mg/15 ml, Injektionslösung
Multiples Myelom, Leichtketten-Amyloidose
01
Z – approved
Package
7680676890018
In trade from / since 8/13/2020
A/R – Authorised / referenced
1 vial(s)
001
Z – approved
Declaration
Component
1800 mg daratumumabum
hyaluronidasum humanum ADNr
histidinum
histidini hydrochloridum monohydricum
735.1 mg sorbitolum
methioninum
polysorbatum 20
aqua ad iniectabile
histidinum
histidini hydrochloridum monohydricum
735.1 mg sorbitolum
methioninum
polysorbatum 20
aqua ad iniectabile
Spezialitätenliste***
SL
-
-
5220.80
None
Yes
10%
No
Authorisation holder
7601001000902
Janssen-Cilag AG
Gubelstrasse 34
6300 Zug (ZG)
Gubelstrasse 34
6300 Zug (ZG)
Date of revision of the text
4/29/2025
Please log in as a company employee using your SIMIS-Login. For further information please see the FAQ.
Data source: Swissmedic, *authorisation holder, **Refdata foundation, ***FOPH.